On Feb. 21, diagnostic and research products manufacturer Immunicon
- Though revenue was up significantly, the company is not really selling many of its diagnostic and research products.
- The company issued $30 million of convertible subordinated notes and warrants maturing in three years, to purchase 1.5 million shares.
- In 2007, the company expects instrument revenue to be in a range of $5.75 million to $7 million and combined reagent, consumable, and service revenue to be in the range of $6 million to $7.5 million.
- The company expects net cash expenditures in the range of $16 million to $18 million for fiscal 2007.
(Figures in thousands, except per-share data)
Income Statement Highlights
|
Q4 2006 |
Q4 2005 |
Change |
|
|---|---|---|---|
|
Sales |
$2,982.0 |
$1,550.0 |
92.4% |
|
Net Profit |
($7,671.0) |
($5,661.0) |
N/A |
|
EPS |
($0.28) |
($0.21) |
N/A |
|
Diluted Shares |
27,664.6 |
27,536.7 |
0.5% |
Get back to basics with a look at the income statement.
Margin Checkup
|
Q4 2006 |
Q4 2005 |
Change* |
|
|---|---|---|---|
|
Gross Margin |
(11.2%) |
33.9% |
(45.1) |
|
Operating Margin |
(206.4%) |
(383.4%) |
176.9 |
|
Net Margin |
(257.2%) |
(365.2%) |
108.0 |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$51,533 |
$42,594 |
21.0% |
|
Accounts Rec. |
$1,402 |
$825 |
69.9% |
|
Inventory |
$3,966 |
$3,223 |
23.1% |
|
Liabilities |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Accounts Payable |
$1,743 |
$938 |
85.8% |
|
Long-Term Debt |
$22,569 |
$3,115 |
624.5% |
Learn the ways of the balance sheet.
Cash Flow Highlights
A statement of cash flows was not provided. Boo!
Find out why Fools always follow the money.
Related Companies:
-
Nanogen
(NASDAQ:NGEN) -
Affymetrix
(NASDAQ:AFFX) -
Varian
(NASDAQ:VARI) -
Illumina
(NASDAQ:ILMN)
Related Foolishness:
- Varian Beams In Results
- The Best Small Cap for 2007: American Science & Engineering
- Affymetrix Expresses Profits
Affymetrix is a Rule Breakers recommendation. You can find out why with a 30-day free trial of the newsletter.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
